0001140361-23-035731.txt : 20230721 0001140361-23-035731.hdr.sgml : 20230721 20230721211120 ACCESSION NUMBER: 0001140361-23-035731 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230719 FILED AS OF DATE: 20230721 DATE AS OF CHANGE: 20230721 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Helsel Dave CENTRAL INDEX KEY: 0001543753 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-50761 FILM NUMBER: 231103605 MAIL ADDRESS: STREET 1: 400 WOOD ROAD CITY: BRAINTREE STATE: MA ZIP: 02184 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ANGIODYNAMICS INC CENTRAL INDEX KEY: 0001275187 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 113146460 STATE OF INCORPORATION: DE FISCAL YEAR END: 0531 BUSINESS ADDRESS: STREET 1: 14 PLAZA DRIVE CITY: LATHAM STATE: NY ZIP: 12110 BUSINESS PHONE: 5187981215 MAIL ADDRESS: STREET 1: 14 PLAZA DRIVE CITY: LATHAM STATE: NY ZIP: 12110 4 1 form4.xml X0508 4 2023-07-19 0001275187 ANGIODYNAMICS INC ANGO 0001543753 Helsel Dave 14 PLAZA DRIVE LATHAM NY 12110 true SVP Global Operations and R&D false Common Stock 2023-07-19 4 A 0 10789 0 A 28986 D Performance Right 2023-07-19 4 A 0 21578 0 A Common Stock 21578 21578 D Non-Qualified Stock Option (right to buy) 8.92 2023-07-19 4 A 0 22329 0 A 2024-07-19 2033-07-19 Common Stock 22329 22329 D The acquisition of 10,789 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 10,789 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 19, 2024, such that 25% of the restricted stock units will vest on each of July 19, 2024, 2025, 2026 and 2027. Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned over a three-year performance period in accordance with performance metrics as determined by the compensation committee (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)). Any shares that do not vest at the end of the performance period will be forfeited. These stock options vest in four equal annual installments beginning on July 19, 2024, such that 25% of the options will vest on each of July 19, 2024, 2025, 2026 and 2027. /s/ Stephen A. Trowbridge, Attorney in Fact 2023-07-21